Y-MABS THERAPEUTICS INC. - COMMON STOCK
12.40
14-11月-24 12:11:19
15 分の遅延
株式
-0.78
-5.92%
本日の幅
11.50 - 12.97
ISIN
N/A
ソース
NASDAQ
-
16 2 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 1 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 12 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 11 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
31 10 2023 07:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
17 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Publication in Cancers
16 10 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
21 9 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences in September
06 9 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
10 8 2023 16:05:02 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences
02 8 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 8 2023 16:05:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 5 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
08 5 2023 16:01:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28 4 2023 09:00:00 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 4 2023 09:00:02 提供 Nasdaq GlobeNewswire
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 4 2023 09:00:00 提供 Nasdaq GlobeNewswire